Regeneron Pharmaceuticals
REGN
603 hedge funds and large institutions have $35.9B invested in Regeneron Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 80 funds opening new positions, 229 increasing their positions, 201 reducing their positions, and 49 closing their positions.
63% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 49
29% more funds holding in top 10
Funds holding in top 10: 17 → 22 (+5)
29% more capital invested
Capital invested by funds: $27.9B → $35.9B (+$8B)
14% more repeat investments, than reductions
Existing positions increased: 229 | Existing positions reduced: 201
4% more funds holding
Funds holding: 578 → 603 (+25)
0.94% more ownership
Funds ownership: 69.06% → 70% (+0.94%)
9% less call options, than puts
Call options by funds: $1.3B | Put options by funds: $1.44B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$680M |
| 2 |
Jennison Associates
New York
|
+$233M |
| 3 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
+$207M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$182M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$105M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$260M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$246M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$128M |
| 4 |
Renaissance Technologies
New York
|
-$89.9M |
| 5 |
Two Sigma Advisers
New York
|
-$81.2M |
REGN Hedge Fund Activity: Q2 2017 in Review
603 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2017, worth a combined $35.9B — up 29% from $27.9B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new REGN positions and 49 closed out — a net gain of 31 holders — while 229 added to existing stakes and 201 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $680M. The largest seller was Wellington Management Group, cutting an estimated $260M.
- 603 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2017, up from 578 in Q1 2017.
- Funds reported $35.9B of Regeneron Pharmaceuticals stock for Q2 2017, up 29% quarter-over-quarter.
- 80 funds opened new Regeneron Pharmaceuticals positions in Q2 2017 and 49 closed out, a net change of +31 holders.
- The largest Regeneron Pharmaceuticals buyer in Q2 2017 was Janus Henderson Group, an estimated $680M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2017 was Wellington Management Group, an estimated $260M sold.
Based on aggregated 13F filings for Q2 2017.